Patient group
Erwachsene mit einem inoperablen oder metastasierten uvealen Melanom und die HLA (humanes Leukozyten-Antigen)-A*02:01-positiv sind
completed2022-05-01D series
Tebentafusp
Uveales Melanom, HLA-A*02:01-positiv
Open official case page ↗
- Brand
- Kimmtrak
- Manufacturer
- Immunocore Ireland Ltd.
G-BA action
final resolution
2022-10-20
Arzneimittel-Richtlinie/Anlage XII: Tebentafusp (Uveales Melanom, HLA-A*02:01-positiv)
Evidence-checked summary
The G-BA found a hint of considerable added benefit for Erwachsene mit einem inoperablen oder metastasierten uvealen Melanom und die HLA (humanes Leukozyten-Antigen)-A*02:01-positiv sind. The G-BA issued a final resolution on 2022-10-20. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2022-09-05
62 parsed turns
Oral hearing: Tebentafusp (Uveales Melanom, HLA-A*02:01-positiv)
Official Wortprotokoll · 10 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
G22-15
matched
Tebentafusp (uveal melanoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Official assessment PDF · 23 pages
G-BA decisions
Distinct actions and documents
2022-10-20
final resolution
Arzneimittel-Richtlinie/Anlage XII: Tebentafusp (Uveales Melanom, HLA-A*02:01-positiv)
The G-BA found a hint of considerable added benefit for Erwachsene mit einem inoperablen oder metastasierten uvealen Melanom und die HLA (humanes Leukozyten-Antigen)-A*02:01-positiv sind. The G-BA issued a final resolution on 2022-10-20. The official page states that it took effect as follows: aufgehoben. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗gba assessmentNutzenbewertung G-BAOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗iqwig assessmentNutzenbewertung IQWiGOpen ↗